Immunologic Factors: all 3,292 studies that test it
Page 4 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaNot yet recruitingNCT05303727Phase 2
- A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome InhibitorNot yet recruitingNCT05298683Phase 2
- A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant IneligibleRecruitingNCT05280275Phase 1/2
- Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System LymphomaRecruitingNCT05260619Phase 2
- Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary PlasmacytomaRecruitingNCT05248633Phase 2
- Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Phase 3
- Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
- Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus NephritisRecruitingNCT05207358Phase 4
- Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCLNot yet recruitingNCT05186558Phase 2
- Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell LymphomaRecruitingNCT05182957Phase 2
- Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05145400Phase 2
- Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good RespondersRecruitingNCT05136976Phase 3
- Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaRecruitingNCT05099471Phase 2
- Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
- IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.RecruitingNCT05073250Phase 2
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingNCT05041907Phase 2
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT04998669Phase 2
- Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftRecruitingNCT04989491Phase 4
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
- Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMMRecruitingNCT04941937Phase 2
- Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS LymphomaRecruitingNCT04938297Phase 2
- Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaRecruitingNCT04922567Phase 2
- Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCLNot yet recruitingNCT04913103Phase 2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
- Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's DiseaseRecruitingNCT04902703Phase 2
- Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVRecruitingNCT04902443Phase 1
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/2
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingNCT04792502Phase 2
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingNCT04745949Phase 2
- Different Immunosuppressive Treatment in iMNRecruitingNCT04745728Phase 3
- Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaRecruitingNCT04737889Phase 2
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaRecruitingNCT04669171Phase 1/2
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingNCT04661137Phase 2
- Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.RecruitingNCT04627753Phase 2
- Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)RecruitingNCT04589299Phase 4
- Haploidentical HCT for Severe Aplastic AnemiaRecruitingNCT04558736Phase 2
- Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.RecruitingNCT04519476Phase 1
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT04508790Phase 2
- Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT04481815Phase 2
- Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC RearrangementRecruitingNCT04432714Phase 1/2
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingNCT04404088Phase 2
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell LymphomaRecruitingNCT04329130Phase 2
- Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic PurpuraRecruitingNCT04323748Phase 1
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementEnrolling by invitationNCT04323566Phase 2
- CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)RecruitingNCT04318678Phase 1
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)RecruitingNCT04301076Phase 1
- GM-CSF With Post-Transplant CyclophosphamideRecruitingNCT04237623Phase 2
- Stem Cell Transplantation in Crohn's DiseaseRecruitingNCT04224558Phase 1/2
- GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)RecruitingNCT04196413Phase 1
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04129710Phase 2
- MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)RecruitingNCT04110301Phase 1/2
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingNCT04061512Phase 2/3
- Ocrelizumab for Psychosis by AutoimmunityRecruitingNCT03971487Phase 1/2
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 GangliosidosisRecruitingNCT03952637Phase 1/2
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal LymphomaRecruitingNCT03746223Phase 2
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
- Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714RecruitingNCT03691077Phase 3
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/2
- VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaRecruitingNCT03641456Phase 2
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingNCT03630211Phase 2
- Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
- [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS LymphomaRecruitingNCT03569995Phase 2
- Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell LymphomaRecruitingNCT03523975Phase 1/2
- Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic SyndromeRecruitingNCT03501459Phase 3
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingNCT03500731Phase 1/2
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaRecruitingNCT03418038Phase 2
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant RecipientsEnrolling by invitationNCT03292861Phase 2
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/2
- Autologous Stem Cell Transplant for Crohn's DiseaseRecruitingNCT03219359Phase 2
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseaseRecruitingNCT03121001Phase 2
- A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) PatientsRecruitingNCT03110822Phase 1
- Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell LymphomaRecruitingNCT03011814Phase 1/2
- Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)RecruitingNCT02903537Phase 1
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- Human Penile AllotransplantationRecruitingNCT02395497Phase 2/3
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaRecruitingNCT01949129Phase 2/3
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingNCT01861106Phase 2
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic SyndromeRecruitingNCT01624805Phase 2
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingNCT01419561Phase 2
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingNCT00977977Phase 2
- Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaRecruitingNCT00412594Phase 2
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
- A Study of TAK-881 and HyQvia in Healthy AdultsCompletedNCT06895967Phase 1Results posted
- Isa-Pom-Dex in Elderly/Frail Subjects With RRMMActive, not recruitingNCT05911321Phase 2Results posted
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell LymphomaTerminatedNCT05788289Phase 2Results posted
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
- Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.TerminatedNCT05579769Phase 2Results posted
- A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaCompletedNCT05564052Phase 2Results posted
- Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell LymphomaTerminatedNCT05498220Phase 2Results posted
- Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in AdultsCompletedNCT05422365Phase 3Results posted
- Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple MyelomaTerminatedNCT05288062Phase 2Results posted
- Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
- A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisTerminatedNCT05265728Phase 3Results posted
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple SclerosisCompletedNCT05232825Phase 3Results posted